[ad_1]

NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) — The law firm of Kirby McInerney LLP reminds investors that securities class action lawsuits have been filed on behalf of investors in securities of APYX Medical Corporation, Digital Turbine Inc., Teladoc Health, Inc., and Verrica Pharmaceuticals, Inc. Investors have until the deadlines below to apply to the Court to be appointed as lead plaintiff in the lawsuits. Additional information about each case can be found at the links provided below.

APYX Medical Corporation (“Apyx Medical” or the “Company”) (NASDAQ: APYX)

Class Period: May 12, 2021 to March 11, 2022
Pending Court: U.S. District Court for the Middle District of Florida
Lead Plaintiff Deadline: August 5, 2022

The lawsuit alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) a significant number of Apyx Medical’s Advanced Energy products were used for off-label indications; (2) such off-label uses led to an increase in the number of medical device reports filed by Apyx Medical reporting serious adverse events; (3) as a result, the Company was reasonably likely to incur regulatory scrutiny; (4) as a result of the foregoing, the Company’s financial results would be adversely impacted; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

For additional information on the Apyx Medical lawsuit please visit this website.

Digital Turbine Inc. (“Digital Turbine” or the “Company”) (NASDAQ: APPS)

Class Period: August 9, 2021 to May 17, 2022
Pending Court: U.S. District Court for the Western District of Texas
Lead Plaintiff Deadline: August 5, 2022

The lawsuit alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company’s recent acquisitions, AdColony and Fyber, act as agents in certain of their respective product lines; (2) as a result, revenues for those product lines must be reported net of license fees and revenue share, rather than on a gross basis; (3) the Company’s internal control over financial reporting as to revenue recognition was deficient; and (4) as a result of the foregoing, the Company’s net revenues was overstated throughout fiscal 2022; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

For additional information on the Digital Turbine lawsuit please visit this website.

Teladoc Health, Inc. (“Teladoc” or the “Company”) (NYSE: TDOC)

Class Period: October 28, 2021 to April 27, 2022
Pending Court: U.S. District Court for the Southern District of New York
Lead Plaintiff Deadline: August 5, 2022

The lawsuit alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) increased competition, among other factors, was negatively impacting Teladoc’s BetterHelp and chronic care businesses; (2) accordingly, the growth of those businesses was less sustainable than Defendants had led investors to believe; (3) as a result, Teladoc’s revenue and adjusted EBITDA projections for FY 2022 were unrealistic; (4) as a result of all the foregoing, Teladoc would be forced to recognize a significant non-cash goodwill impairment charge; and (5) as a result, the Company’s public statements were materially false and misleading at all relevant times.

For additional information on the Teladoc lawsuit please visit this website.

Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (NASDAQ: VRCA)

Class Period: May 28, 2021 to May 24, 2022
Pending Court: U.S. District Court for the Eastern District of Pennsylvania
Lead Plaintiff Deadline: August 5, 2022

The lawsuit alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) there were manufacturing deficiencies at the facility where Verrica’s contract manufacturer produced bulk solution for VP-102; (2) these deficiencies were not remediated when Verrica resubmitted its NDA for VP-12 for molluscum; (3) the foregoing presented significant risks to Verrica obtaining regulatory approval of VP-102 for molluscum; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

For additional information on the Verrica lawsuit please visit this website.

About Kirby McInerney LLP:

Kirby McInerney is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney’s website: www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts
Kirby McInerney LLP
Thomas W. Elrod, Esq.
(212) 371-6600
investigations@kmllp.com
www.kmllp.com


[ad_2]

Source link